The Food and Drug Administration and the Massachusetts Institute of Technology have agreed to develop an automated system to detect unanticipated problems with prescription drugs and medical devices.
The current system relies on the largely manual assessment of reports voluntarily submitted to the FDA, sometimes months or years after an event has occurred (reference the Vioxx recall). The new automated system is intended to recognize patterns and alert problems much quicker.
